Latest / Deep Values: Value Investing Deep Dives / 【13F】Druckenmiller Sells Nvidia Buys Biotech
Transcript
- 0:00Welcome to the Deep Dive. Today we're going granular,
- 0:03looking into the mind and the playbook of a true legend.
- 0:07We are. We're dissecting the Q32025
- 0:09portfolio filing from Stanley Druckenmiller's Duquesne family
- 0:13office, all $4 billion of it. And this isn't just a list of
- 0:16stocks. When you really get into it, you
- 0:18see it's, well, it's a macroeconomic thesis laid.
- 0:21Bare, it absolutely is. And the signal for this quarter
- 0:24is well, it's stark. The man who arguably rode the AI
- 0:29infrastructure wave better than anyone has just performed a
- 0:32massive, decisive structural rotation.
- 0:35The. Scale of that rotation is what
- 0:36really grabs you. We're talking about a huge pivot
- 0:38away from, you know, the pure semiconductor trade, the AI
- 0:42hardware boom, and into something new.
- 0:44He's moved into a very deliberate barbell strategy.
- 0:47On one end you have things like biotechnology, on the other
- 0:50applied AI and good old fashioned industrial capacity.
- 0:53He's basically shifting from selling the and shovels in the
- 0:56gold rush to owning the most efficient gold mines.
- 0:58That's a perfect way to put it, but the most astonishing number,
- 1:01the thing that tells you everything about his mindset, is
- 1:04the activity. Yeah, let's talk about that.
- 1:06In a single quarter, he had 65 total holdings.
- 1:10He added 29 new ones. And sold out of 33 completely.
- 1:14Which results in a, get this, a 92.3% quarterly turnover rate.
- 1:21It's unbelievable. I mean, that's just, that's not
- 1:23investing, it's surgical. So given that staggering level
- 1:27of activity, what's the philosophy, What's the
- 1:29foundation that lets him make these huge high conviction calls
- 1:33so quickly? To understand the portfolio, you
- 1:36have to understand the man. Druckenmiller became famous as
- 1:39the brain behind the trade that, you know, broke the Bank of
- 1:42England back in 92. The billion dollar trade.
- 1:45A billion dollars, but he's not really a stock picker at heart.
- 1:48He is arguably the greatest macro trader of his generation.
- 1:52We're talking 30% average annual returns for three decades with
- 1:56no down years. That kind of track record only
- 1:59comes from having a very clear set of rules.
- 2:01Let's start with his first pillar.
- 2:03Liquidity is king. Yes, this is the lens for
- 2:07everything else. He has this famous quote,
- 2:10earnings don't move the overall market, it's the Federal Reserve
- 2:13Board. He's always focused on the
- 2:15movement of liquidity. So what does this frantic
- 2:19rotation tell us about his view on liquidity right now?
- 2:22It suggests he's wary. It implies he sees a world where
- 2:26that easy money, that liquidity might be tightening up.
- 2:30So he's shifting into companies that can win on their own merit,
- 2:33you know, through their own innovation, not just because the
- 2:36market tide is lifting all boats.
- 2:38And he can make those specific bets because of his second
- 2:40pillar, which is the doctrine of concentration, right?
- 2:43He famously rejects diversification.
- 2:45He sees it as a edge against ignorance.
- 2:48He's more of a Mark Twain guy. Put all your eggs in one basket
- 2:51and watch the basket very carefully.
- 2:53Exactly, and the Q3 data just screams this.
- 2:56His top 10 holdings make up 53.93% of the entire portfolio.
- 3:00Wow. But you can't have that kind of
- 3:02concentration without the third rule, which is the most
- 3:04critical. 1 he learned from Soros.
- 3:06It's the idea of being a pig. Which sounds bad, but what does
- 3:09it mean in practice? It means you go huge when you're
- 3:12right. You size up aggressively when
- 3:14your conviction is high. But, and this is the key, the
- 3:19absolute second year thesis breaks or the risk reward
- 3:22changes. You get out immediately.
- 3:25No ego. And that explains the 92%
- 3:28turnover. It's the only thing that does.
- 3:30It's why he can make a fortune on a stock like NVIDIA and then
- 3:33just walk away. Completely, which brings us
- 3:35right to the portfolio's current design, this Q32025 barbell
- 3:40strategy. Right, It's a structure built
- 3:42for an uncertain world. It has 1 foot planted
- 3:45defensively and the other swinging for the fences.
- 3:47That's it. The defensive anchor is huge.
- 3:49Almost 30% of the portfolio is in healthcare and biotech.
- 3:53That's growth that isn't tied to GDP.
- 3:55It's the ballast. And the aggressive wing is where
- 3:57he's looking for that real upside.
- 3:59High beta tech like Amazon and Meta, plus some global plays
- 4:02like the Emerging Markets ETF and regional champions like
- 4:05Kupang. But the biggest tactical shift,
- 4:08the thing we have to really dig into, is the AI pivot.
- 4:11He sold out of NVIDIA completely.
- 4:13Completely. The thesis here is pretty clear.
- 4:15The pick and shovel phase of the AI gold rush, selling the chips,
- 4:18the raw infrastructure has gotten too expensive.
- 4:21The easy money has been made. So if he's not buying the
- 4:24Sables, where is he digging? Why exit the most obvious winner
- 4:28of the last few years? Because the value is moving up
- 4:31the stack, it's shifting from the infrastructure to the
- 4:33application layer. He's now buying the companies
- 4:36that are using all that computing power to become
- 4:38insanely efficient. Like Meta for AD targeting or
- 4:41Amazon for logistics. And most importantly, a company
- 4:44like Natera for genomic analysis, the next big wins will
- 4:48come from proprietary performance, not from selling
- 4:51what's becoming a commodity. That focus on application brings
- 4:54us straight to his highest conviction zone, healthcare.
- 4:57I mean, the fact that his top three positions are all in this
- 5:00one sector, it's a massive statement.
- 5:02It's an overwhelming bet on bio innovation as a secular growth
- 5:06theme. So let's start with the crown
- 5:07jewel Natera, ticker NTRA. It's 12.74% of the portfolio, a
- 5:13huge position. Natera is all about a paradigm
- 5:16shift in how we re monitor cancer.
- 5:18They're leaders in cell free DNA testing, which you might know as
- 5:22liquid biopsies. Specifically, their platform is
- 5:25called Signatera. OK, So for those of us not deep
- 5:28in the genomics world, what is molecular residual disease or
- 5:31MRD and why is finding it so revolutionary?
- 5:35So MRD is basically the tiny amount of cancer cells that can
- 5:38be left behind after treatment. Historically, you'd wait for ACT
- 5:42or an MRI scan to see if the tumor came back.
- 5:44But by then it's already grown back to a visible size.
- 5:47Exactly signature is different. It tracks the specific mutations
- 5:51of a patient's tumor in their blood.
- 5:52It can detect recurrence months, sometimes years earlier than an
- 5:56imaging scan. That's a game changer.
- 5:58It's becoming the standard of care.
- 5:59And it creates A Moat with over 12 million test process.
- 6:04They have this massive data set that just makes their tests
- 6:06better and better. It's a network effect.
- 6:08It's a classic defensible business transformation.
- 6:11Now let's look at #2 ends Med or INSM.
- 6:15This is almost 9% of the portfolio and he upped his
- 6:17position by over 7% this quarter.
- 6:20The conviction here seems really clear.
- 6:22It's tied to a single de risked event.
- 6:25It is. It was the FDA approval in
- 6:27August 2025 for their drug Brensukatib, which is being sold
- 6:31as Brinsupri. And this was a big deal because.
- 6:34It's the first and only approved treatment for something called
- 6:37non cystic fibrosis, Bronchiectasis and CFB.
- 6:41It's a nasty chronic lung disease effects about half a
- 6:45million people in the US alone who until now had zero approved
- 6:49therapies. So the thesis is just a massive
- 6:52unmet need. That's the bet some analysts
- 6:55worry about, you know, commercial launch execution.
- 6:57But Druckenmiller is betting that when you were the only
- 6:59solution for half a million desperate patients, the market
- 7:02penetration is going to be incredibly steep.
- 7:04The risk has moved from the lab to the marketplace, and he's the
- 7:07stock hasn't caught up to that reality.
- 7:08So we have two high growth plays.
- 7:10The third leg of this healthcare stool is Teva Pharmaceutical TEV
- 7:14and 8.5% weight. This one feels different.
- 7:17It feels like a value play. It's a classic turn around
- 7:19story. A good company with a bad
- 7:21balance sheet. TAVA was crushed for years by
- 7:24enormous debt and that whole opioid litigation mess.
- 7:28Right. By 2025 they've basically
- 7:30settled the legal stuff and are now just aggressively paying
- 7:32down debt. So it's a deleveraging story.
- 7:35As the debt shrinks, the value of the equity expands because
- 7:38more the cash flow goes to shareholders instead of debt
- 7:41payments. That's it exactly.
- 7:42Plus, their speciality drugs like Austedo are growing and
- 7:46they're a giant in the biosimilars market.
- 7:48It's a cash generating machine that nicely balances the more
- 7:52binary risks of the pure biotech bats.
- 7:55OK, so let's pivot from the biological to the digital.
- 7:59Even though he rotated out of chip designers, he kept one
- 8:02critical holding Taiwan Semiconductor TSM, still over 5%
- 8:07of the portfolio. TSM is the ultimate toll taker.
- 8:10It's a de facto monopoly on the most advanced chip
- 8:12manufacturing. Yeah, it doesn't matter if the
- 8:14ultimate winner in AI is Amazon or Apple or someone else.
- 8:18They all have to go through TSMC's factories.
- 8:20They all be the toll. It's a much safer, more
- 8:22reasonably valued way to play the long term growth in
- 8:25computing power. And Speaking of Amazon, he was a
- 8:27new buyer there and also in Meta Platforms.
- 8:31How do you square Meta as an efficiency play when they're
- 8:34still pouring billions into the metaverse?
- 8:37That's the key friction point, isn't it?
- 8:39The bet isn't on the metaverse. The bet is that right now Meta
- 8:44is the cheapest mega cap stock out there, and the conviction
- 8:49comes from Zuckerberg's whole year of efficiency push.
- 8:52They are using AI right now to make their core ad business
- 8:57dramatically more profitable. That's the driver for the stock,
- 9:00almost regardless of what happens with the metaverse long
- 9:02term. OK, let's switch to his global
- 9:04view. He's not just buying a broad
- 9:05index, he's targeting very specific winner take all
- 9:09regional monopolies. Exactly.
- 9:10Look at coup paying in South Korea.
- 9:12They basically won that market with their incredible logistics,
- 9:15their dawn delivery model, and now that the heavy spending
- 9:18phase is over, their margins are exploding.
- 9:20And they're exporting that model to other places like Taiwan.
- 9:23Right. And then you have MercadoLibre
- 9:24or MLI in Latin America, which is really two dominant
- 9:28businesses in one. The ecommerce platform and the
- 9:30fintech arm. That's it.
- 9:32Mercado Pago, the fintech part, is essentially a digital bank
- 9:36for the massive unbanked population in Latin America.
- 9:40It's growing faster and has higher margins than the retail
- 9:43business. It's a monster compounder.
- 9:46Let's move to the physical world for a minute.
- 9:48He made a big addition to Wabtec, the rail tech company.
- 9:52Up 77%. This smells like a green
- 9:55friction trade. Rail is, by a huge margin, the
- 9:58most fuel efficient way to move freight.
- 10:00As supply chains move closer to home and the world tries to
- 10:03decarbonize, rail just becomes more and more important.
- 10:06And Woptech provides the tech to make it all work.
- 10:09And they have an $8 billion backlog that gives you
- 10:11incredible visibility into future earnings no matter what
- 10:14the economy does in the short term.
- 10:16One of the most interesting new positions, for me at least, is
- 10:19Figure Technology Solutions FAGR.
- 10:22This is a fascinating 1 figure is tapping into a huge problem
- 10:26in the market right now. You have millions of homeowners
- 10:29with record high equity in their homes, but they're locked in to
- 10:33these super low rate mortgages they.
- 10:35Don't want to refinance and lose their 3% rate?
- 10:37Of course not. So Figure uses the Providence
- 10:40blockchain to totally revolutionize how you get a home
- 10:44equity line of credit AEPLOC. Why blockchain?
- 10:47What's the advantage? Speed.
- 10:49The blockchain is an unchangeable, instantly
- 10:51verifiable record. It cuts the approval time for a
- 10:54EE LOC from weeks doing title searches, all the old legal
- 10:58stuff down to just minutes. Wow.
- 11:00It's a pure bet on the real world utility of blockchain to
- 11:03make a huge financial market faster and cheaper.
- 11:06All right. Finally, we have to talk about
- 11:07how he protects the portfolio, the hedges.
- 11:10He's got the Emerging Markets ETF, EE, M and some options on
- 11:14the S&P 500. The EEM position is really a
- 11:16dollar hedge. Druckenmiller has been very
- 11:19public about his concerns over the US fiscal path the national
- 11:22debt, so betting on growth outside the US is a way to
- 11:25position for potential dollar weakness.
- 11:28And what about the call options on the Spy and the IWM, the
- 11:31Russell 2000? That's a classic melt up hedge.
- 11:34It's defined risk exposure. It lets him participate if
- 11:36there's some kind of, you know, irrational liquidity fueled
- 11:39rally in the broad market. Without having to sell his
- 11:41favorite stocks to buy the index.
- 11:43Exactly, it's a cheap insurance policy for being wrong about a
- 11:46market top. It lets him stay concentrated.
- 11:49So after all that, what's the big take away for you, the
- 11:52listener? Let's try to synthesize this.
- 11:54The core conclusion seems to be that the era of just buying the
- 11:57market of broad beta is over. It's completely over.
- 12:02We are deep in a market of dispersion.
- 12:04That means the winners and losers are going to be driven by
- 12:07company specific factors, not the overall market direction.
- 12:11Alpha is now about identifying these unique, idiosyncratic
- 12:14business transformations. Absolutely.
- 12:16The playbook is simple, but it's not easy.
- 12:19You're betting on curing disease with Natera and Insmed.
- 12:22You're optimizing global logistics with Coupang and
- 12:24Wabtec, and you're owning the new efficiency platforms like
- 12:28Amazon and Meta. So the takeaways are pretty
- 12:30sharp. One healthcare innovation is the
- 12:32new secular growth engine. It's not tied to the economy.
- 12:352IN AI, the smart money is rotating from the hardware to
- 12:38the application layer, from the chips to the platforms.
- 12:41And three, globally you hunt for those winner take all monopolies
- 12:45that can deliver predictable growth in their specific
- 12:47regions. Which brings us back to this
- 12:49fundamental tension in his whole philosophy.
- 12:52Druckenmiller's foundational belief is that liquidity moves
- 12:55the market. That's the macro view.
- 12:57But his portfolio is the definition of micro,
- 13:01overwhelmingly concentrated in companies with very specific
- 13:04idiosyncratic catalysts. A drug approval, A genomic
- 13:07breakthrough, A balance sheet repair.
- 13:10So we'll leave you with this question to think about.
- 13:12In a volatile tightening environment where that tide of
- 13:14liquidity isn't lifting every boat anymore, is this the only
- 13:17way left to win? Is identifying these specific
- 13:20microlevel transformations now the best, or maybe even the only
- 13:23defense against all the macro noise?